MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)

Core Points - MediciNova, Inc. has received a $22 million grant from the NIH to conduct an Expanded Access Protocol for MN-166 (ibudilast) in ALS patients [1][2][3] - The EAP will allow ALS patients not eligible for the COMBAT-ALS trial to access MN-166 and will evaluate neurofilament light as a biomarker for neuron damage [2][3] - MN-166 is in late-stage clinical development for various neurodegenerative diseases and has received Orphan Drug Designation and Fast Track Designation from the FDA [4][5][6] Company Overview - MediciNova is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory, fibrotic, and neurodegenerative diseases [6] - The company has a pipeline of 11 clinical programs, with MN-166 being its lead asset currently in Phase 3 trials for ALS and DCM [6] - MediciNova has a strong track record of securing government grants for clinical trials [6]